Drug profile · INN
tocilizumab-aazg
TYENNE
tocilizumab-aazg (TYENNE) is a interleukin-6 receptor alpha subunit inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — tocilizumab-aazg
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
tocilizumab-aazg (TYENNE) is a interleukin-6 receptor alpha subunit inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-6 receptor alpha subunit inhibitor
Primary target: Interleukin-6 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tocilizumab-aazg?
tocilizumab-aazg (TYENNE) is a interleukin-6 receptor alpha subunit inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for tocilizumab-aazg?
TYENNE is a marketed brand name for tocilizumab-aazg. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tocilizumab-aazg?
tocilizumab-aazg has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.